SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3255)2/26/2014 4:35:37 PM
From: jaybe  Respond to of 4474
 
And many detours in optimization lead to improvements. When Pona was still known as AP23464 it did not inhibit the T315i mutation, several modifications and two years later it did.



To: Biomaven who wrote (3255)2/26/2014 7:09:21 PM
From: tejek  Respond to of 4474
 
>>Why does it take so long to get into clinical trials?

Because after you have settled on the final candidate, you still have to perform animal tox studies and scale up production.

Oops. I thought the animal tox studies helped determine the candidate. Didn't realize they came after. Thanks.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News